NCT04883775 - Study of a New Technique for Imaging Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions

Pancreatic CancerTumors That Express CA19-9

Interventions

DRUG

MVT-2163

MVT-2163 is administered intravenously as a PET imaging agent.

DRUG

MVT-5873

MVT-5873 will be administered intravenously over at least 60 minutes.

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester (Consent only), Harrison

Memorial Sloan Kettering Nassau (Consent Only), Uniondale

Memorial Sloan Kettering Cancer Center @ Commack (Consent Only), Commack

Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge

Memorial Sloan Kettering Monmouth (Consent only), Middletown

Memorial Sloan Kettering Bergen (Consent only ), Montvale